Bush veto fuels orphan drug act uncertainties.

Orphan Drug Act. Winners to keep all.

Evolution and current status of the Orphan Drug Act.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Drug development. Orphan drug windfalls?

Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act.

Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.

Diazoxide--an orphan drug?

Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Judge upends 340B orphan drug exclusion.

Editorial: Orphan GPCRs As Emerging Drug Targets.

A new kind of orphan drug?

Veto in vivo?

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

1978 Drug Regulation Reform Act.

The Massachusetts drug formulary act.

Boolean networks with veto functions.

Successful development of an orphan drug for the pediatric population.

Insurance companies' perspectives on the orphan drug pipeline.

Challenges in orphan drug development and regulatory policy in China.

From promising molecules to orphan drugs: Early clinical drug development.

Suggest Documents

Orphan Drug Act. Winners to keep all.

Evolution and current status of the Orphan Drug Act.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Drug development. Orphan drug windfalls?

Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act.

Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.

Diazoxide--an orphan drug?

Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Judge upends 340B orphan drug exclusion.

Editorial: Orphan GPCRs As Emerging Drug Targets.

A new kind of orphan drug?

Veto in vivo?

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

1978 Drug Regulation Reform Act.

The Massachusetts drug formulary act.

Boolean networks with veto functions.

Successful development of an orphan drug for the pediatric population.

Insurance companies' perspectives on the orphan drug pipeline.

Challenges in orphan drug development and regulatory policy in China.

From promising molecules to orphan drugs: Early clinical drug development.

Bush veto fuels orphan drug act uncertainties.

Recommend Documents

Follow Us